Hironobu Yasui

Dr. Hironobu Yasui

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2012 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
TYTohru Yamamori
Tohru Yamamori
HYHironobu Yasui
Hironobu Yasui
MYMasayuki Yamazumi
Masayuki Yamazumi
YWYusuke Wada
Yusuke Wada
YNYoshinari Nakamura
Yoshinari Nakamura
OIOsamu Inanami
Osamu Inanami

14 December 2010 in Cancer Research
Verified
Journal Article
Open access
PDF file
SMShingo Matsumoto
Shingo Matsumoto
HYHironobu Yasui
Hironobu Yasui
JMJames B. Mitchell
James B. Mitchell
MKMurali C. Krishna
Murali C. Krishna
Cycling hypoxia is now a well-recognized phenomenon in animal and human solid tumors. Cycling hypoxia can exist more than 100-μm distances from a microvessel, and some of these regions have been shown to exist adjacent to normal tissue. Fluctuations in pO2 of approximately 20 mm Hg can occur with periodicities of minutes to hours and even days. These fluctuations have been attributed to changes in erythrocyte flux, perfusion, and also development of newer vascular networks. Cycling hypoxia has been shown to induce the expression of hypoxia-inducible transcription factor-1α (HIF-1α) and also confer tumor cells and tumor vascular endothelial cells with enhanced prosurvival pathways, making tumors less responsive to radiation and chemotherapy. Imaging of cycling hypoxia in tumors can provide capabilities to help plan appropriate treatment, by taking into account the magnitude and frequency of fluctuations and also their locations adjacent to normal tissue. Electron paramagnetic resonance imaging (EPRI) provides the ability to distinguish chronic and cycling hypoxic regions and has the required spatial and temporal resolutions to provide quantitative maps of tumor pO2. EPRI can serve as a valuable tool in examining tumor pO2 longitudinally in response to treatment and in an experimentally chosen time window to spatially map fluctuations in pO2 noninvasively in animal models of implanted or orthotopic tumors, with a potential for human applications. Cancer Res; 70(24); 10019–23. ©2010 AACR.

4 December 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YSYuki Shibata
Yuki Shibata
HYHironobu Yasui
Hironobu Yasui
KHKei Higashikawa
Kei Higashikawa
NMNaoki Miyamoto
Naoki Miyamoto
YKYuji Kuge
Yuji Kuge
High concentrations of antioxidants in cancer cells are huge obstacle in cancer radiotherapy. Erastin was first discovered as an inducer of iron-dependent cell death called ferroptosis accompanied by antioxidant depletion caused by cystine glutamate antiporter inhibition. Therefore, treatment with erastin is expected to potentially enhance cellular radiosensitivity. In this study, we investigated the influence of treatment with erastin on the radiation efficiency against cancers. The clonogenic ability, glutathione peroxidase 4 (GPX4) expression, and glutathione concentration were evaluated using HeLa and NCI-H1975 adenocarcinoma cell lines treated with erastin and/or X-ray irradiation. For in vivo studies, NCI-H1975 cells were transplanted in the left shoulder of nude mice, and then radiosensitizing effect of erastin and glutathione concentration in the cancer were evaluated. Treatment with erastin induced ferroptosis and decreased the concentration of glutathione and GPX4 protein expression levels in the two tumor cell lines. Moreover, erastin enhanced X-ray irradiation-induced cell death in both human tumor cell lines. Furthermore, erastin treatment of a tumor-transplanted mouse model similarly demonstrated the radiosensitizing effect and decrease in intratumoral glutathione concentration in the in vitro study. In conclusion, our study demonstrated the radiosensitizing effect of erastin on two adenocarcinoma cell lines and the tumor xenograft model accompanied by glutathione depletion, indicating that ferroptosis inducers that reduce glutathione concentration could be applied as a novel cancer therapy in combination with radiotherapy.

12 October 2011 in Cancer Research
Verified
Journal Article
Closed access
PDF file
SMShingo Matsumoto
Shingo Matsumoto
SBSonny Batra
Sonny Batra
KSKeita Saito
Keita Saito
HYHironobu Yasui
Hironobu Yasui
RCRajani Choudhuri
Rajani Choudhuri
MKMurali C. Krishna
Murali C. Krishna
Structural and functional abnormalities in tumor blood vessels impact the delivery of oxygen and nutrients to solid tumors, resulting in chronic and cycling hypoxia. Although chronically hypoxic regions exhibit treatment resistance, more recently it has been shown that cycling hypoxic regions acquire prosurvival pathways. Angiogenesis inhibitors have been shown to transiently normalize the tumor vasculatures and enhance tumor response to treatments. However, the effect of antiangiogenic therapy on cycling tumor hypoxia remains unknown. Using electron paramagnetic resonance imaging and MRI in tumor-bearing mice, we have examined the vascular renormalization process by longitudinally mapping tumor partial pressure of oxygen (pO2) and microvessel density during treatments with a multi-tyrosine kinase inhibitor sunitinib. Transient improvement in tumor oxygenation was visualized by electron paramagnetic resonance imaging 2 to 4 days following antiangiogenic treatments, accompanied by a 45% decrease in microvessel density. Radiation treatment during this time period of improved oxygenation by antiangiogenic therapy resulted in a synergistic delay in tumor growth. In addition, dynamic oxygen imaging obtained every 3 minutes was conducted to distinguish tumor regions with chronic and cycling hypoxia. Sunitinib treatment suppressed the extent of temporal fluctuations in tumor pO2 during the vascular normalization window, resulting in the decrease of cycling tumor hypoxia. Overall, the findings suggest that longitudinal and noninvasive monitoring of tumor pO2 makes it possible to identify a window of vascular renormalization to maximize the effects of combination therapy with antiangiogenic drugs. Cancer Res; 71(20); 6350–9. ©2011 AACR.

14 August 2010 in Cancer Research
Verified
Journal Article
Closed access
PDF file
HYHironobu Yasui
Hironobu Yasui
SMShingo Matsumoto
Shingo Matsumoto
NDNallathamby Devasahayam
Nallathamby Devasahayam
JMJeeva P. Munasinghe
Jeeva P. Munasinghe
RCRajani Choudhuri
Rajani Choudhuri
MKMurali C. Krishna
Murali C. Krishna
Tumors exhibit fluctuations in blood flow that influence oxygen concentrations and therapeutic resistance. To assist therapeutic planning and improve prognosis, noninvasive dynamic imaging of spatial and temporal variations in oxygen partial pressure (pO2) would be useful. Here, we illustrate the use of pulsed electron paramagnetic resonance imaging (EPRI) as a novel imaging method to directly monitor fluctuations in oxygen concentrations in mouse models. A common resonator platform for both EPRI and magnetic resonance imaging (MRI) provided pO2 maps with anatomic guidance and microvessel density. Oxygen images acquired every 3 minutes for a total of 30 minutes in two different tumor types revealed that fluctuation patterns in pO2 are dependent on tumor size and tumor type. The magnitude of fluctuations in pO2 in SCCVII tumors ranged between 2- to 18-fold, whereas the fluctuations in HT29 xenografts were of lower magnitude. Alternating breathing cycles with air or carbogen (95% O2 plus 5% CO2) distinguished higher and lower sensitivity regions, which responded to carbogen, corresponding to cycling hypoxia and chronic hypoxia, respectively. Immunohistochemical analysis suggests that the fluctuation in pO2 correlated with pericyte density rather than vascular density in the tumor. This EPRI technique, combined with MRI, may offer a powerful clinical tool to noninvasively detect variable oxygenation in tumors. Cancer Res; 70(16); 6427–36. ©2010 AACR.

7 September 2013 in FEBS Letters
Verified
Journal Article
Closed access
TYTohru Yamamori
Tohru Yamamori
SMShunsuke Meike
Shunsuke Meike
MNMasaki Nagane
Masaki Nagane
HYHironobu Yasui
Hironobu Yasui
OIOsamu Inanami
Osamu Inanami